Magnetic Resonance in Cancer Research
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 15 August 2024 | Viewed by 1233
Special Issue Editors
Interests: magnetic resonance spectroscopic imaging technology for early detection of cancer treatment response; bacteria-based cancer therapy and imaging; cancer metastasis
Interests: applying magnetic resonance imaging and magnetic resonance spectroscopy to study the tumor microenvironment; early detection of ovarian cancer; cancer cachexia; theranostic imaging
Special Issue Information
Dear Colleagues,
Since Rabi’s first experiment on nuclear magnetic resonance (NMR) in 1938, magnetic resonance has become an indispensable medical imaging modality in cancer diagnosis and treatment monitoring. NMR-based metabolomics is now employed for tumor metabolic profiling to evaluate patients’ response to cancer treatment. NMR is also a powerful tool in structural biology. The structural characterization of protein interactions with small molecules has led to novel drug designs.
We are pleased to invite you to contribute to this Special Issue of Cancers entitled ”Magnetic Resonance in Cancer Research”, focusing on cancer imaging for cancer diagnosis and treatment monitoring, as well as cellular and molecular imaging for precision medicine in order to improve patient outcomes. This Special Issue aims to collect research articles addressing magnetic resonance in cancer research, including pre-clinical studies and clinical investigations on all cancer types.
In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the following: (a) clinical MRI of cancer and machine learning; (b) diffusion-weighted MRI (DWI) in cancer treatment assessment; (c) fast proton MRSI in cancer biomarker detection; (d) MRI evaluation of cardiotoxicity of cancer therapy; (e) PET/MRI of cancer; (f) MR characterization of tumor oxygenation; (g) molecular imaging of cancer; (h) hyperpolarization C-13 MRS in cancer metabolic imaging; (i) deuterium MRS in cancer biomarker imaging; and (j) F-19 MRI in cancer drug metabolism and cell tracking, etc.
We look forward to receiving your contributions.
Dr. Qiuhong He
Dr. Marie-France Vidaver
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- magnetic resonance
- cancer
- MRI
- MRS
- MRSI
- NMR
- DWI
- MR
- molecular imaging